"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...
Cathie Wood's ARK ETFs have made their daily trades public for Thursday, January 23rd, 2025, displaying a strategic shift in ...
Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...
Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...
Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop new hardware and software optimized for the healthcare sector. The effort ...
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on AbSci (ABSI – Research Report) today and set a price target of $7.00.
Absci (ABSI) and Owkin announced a partnership bringing together two leading AI platforms to rapidly discover and design ...
AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the company entered into a strategic collaboration with Advanced Micro Devices Inc ...
According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...